Testing a tumor marker to predict colon cancer relapse risk
Part of Cancer, Digestive system clinical trials.
This study looks at whether a lab test on your tumor can better predict the chance that non-metastatic colon cancer will come back after surgery. Researchers will compare relapse risk using the Immunoscore® test to help guide follow-up and treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 80.
- You have colon cancer confirmed by biopsy (colon adenocarcinoma).
- You already had curative surgery for stage I, II, or III colon cancer (not cancer that has spread to distant organs).
- Your cancer stage is T1 to T4 and lymph nodes are N0, N1, or N2.
- Your doctors plan for you to receive about 6 months of chemotherapy after surgery.
- You can and agree to sign consent, and you agree to use a tumor sample for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at immune cells (NK cells and ImmunoScore) in the blood of people with rectal cancer that hasn't spread. It may help doctors learn more about how the immune system responds to standard chemoradiation treatment.
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This study looks at your immune system and your tumor to help build a model that predicts if cancer might come back after surgery. The goal is to improve how we plan follow-up care and possibly guide future treatments.
This study looks at how the immune system reacts to colorectal cancer in the body. It aims to understand immune responses better, which may help improve future treatments.
This study looks for biological markers (clues in your body) to predict where colorectal cancer might come back or spread. It aims to help doctors personalize follow-up care and treatment decisions for each patient.
Hear when a new Non-metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.